HCPLive Network

2011 ACC VIDEO: Dr. Joe Kim Talks with Airstrip Technologies

Dr. Joe Kim speaks with Bruce Brandes of Airstrip Technologies about the company's recent announcement of its partnership with General Electric (GE). Brandes says that the partnership will allow Airstrip to leverage GE's infrastructure and technology to help expand opportunities for Airstrip's mobility platform to be implemented worldwide.



Further Reading
Results of a large international study known as SIGNIFY showed ivabradine offered no benefit to patients who had stable coronary artery disease without clinical heart failure (CHF).
Novartis plans to soon file a new drug application with the US Food and Drug Administration (FDA) for its investigational heart failure drug LCZ696. A report showing the drug works better than enalapril to prevent adverse cardiac events was released at the European Society of Cardiology Congress in Barcelona, Spain Aug. 30 and published online in the New England Journal of Medicine (NEJM).
The quality of Americans' diets has improved somewhat but remains poor overall, and dietary disparity between the rich and poor is growing, a new study shows. Education also played a role in dietary quality, which was lowest and improved more slowly among people who had 12 years or less of school, according to the study published online Sept. 1 in JAMA Internal Medicine.
For patients with ST-segment elevation myocardial infarction, prehospital administration of ticagrelor is not associated with improved coronary reperfusion, according to a study published online Sept. 1 in the New England Journal of Medicine. The study was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 30 to Sept. 3 in Barcelona, Spain.
For patients with stable coronary artery disease without clinical heart failure, ivabradine does not improve outcomes, according to a study published online Aug. 31 in the New England Journal of Medicine. The study was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 30 to Sept. 3 in Barcelona, Spain.
For patients after an acute coronary syndrome event, darapladib inhibition of lipoprotein-associated phospholipase A2 does not reduce the risk of major coronary events, according to a study published online Aug. 31 in the Journal of the American Medical Association. The study was published to coincide with the annual European Society of Cardiology Congress, held from Aug. 30 to Sept. 3 in Barcelona, Spain.
Nine percent of top-selling packaged food products in the United States contain partially hydrogenated oils, with most of these products reporting 0 grams of trans fat per serving, according to a study published Aug. 28 in the U.S. Centers for Disease Control and Prevention's Preventing Chronic Disease.
More Reading
Results of a large international study known as SIGNIFY showed ivabradine offered no benefit to patients who had stable coronary artery disease without clinical heart failure (CHF).